Mitochondrial genetic variation and risk of chronic kidney disease and acute kidney injury in UK Biobank participants
- PMID: 38349571
- PMCID: PMC10881785
- DOI: 10.1007/s00439-023-02615-4
Mitochondrial genetic variation and risk of chronic kidney disease and acute kidney injury in UK Biobank participants
Abstract
Experimental models suggest an important role for mitochondrial dysfunction in the pathogenesis of chronic kidney disease (CKD) and acute kidney injury (AKI), but little is known regarding the impact of common mitochondrial genetic variation on kidney health. We sought to evaluate associations of inherited mitochondrial DNA (mtDNA) variation with risk of CKD and AKI in a large population-based cohort. We categorized UK Biobank participants who self-identified as white into eight distinct mtDNA haplotypes, which were previously identified based on their associations with phenotypes associated with mitochondrial DNA copy number, a measure of mitochondrial function. We used linear and logistic regression models to evaluate associations of these mtDNA haplotypes with estimated glomerular filtration rate by serum creatinine and cystatin C (eGFRCr-CysC, N = 362,802), prevalent (N = 416 cases) and incident (N = 405 cases) end-stage kidney disease (ESKD), AKI defined by diagnostic codes (N = 14,170 cases), and urine albumin/creatinine ratio (ACR, N = 114,662). The mean age was 57 ± 8 years and the mean eGFR was 90 ± 14 ml/min/1.73 m2. MtDNA haplotype was significantly associated with eGFR (p = 2.8E-12), but not with prevalent ESKD (p = 5.9E-2), incident ESKD (p = 0.93), AKI (p = 0.26), or urine ACR (p = 0.54). The association of mtDNA haplotype with eGFR remained significant after adjustment for diabetes mellitus and hypertension (p = 1.2E-10). When compared to the reference haplotype, mtDNA haplotypes I (β = 0.402, standard error (SE) = 0.111; p = 2.7E-4), IV (β = 0.430, SE = 0.073; p = 4.2E-9), and V (β = 0.233, SE = 0.050; p = 2.7E-6) were each associated with higher eGFR. Among self-identified white UK Biobank participants, mtDNA haplotype was associated with eGFR, but not with ESKD, AKI or albuminuria.
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
The results presented in this paper have not been published previously in whole or part, except in abstract format. M.G.S. has served on advisory boards for AstraZeneca, Bayer, and Boerhinger Ingelheim, and receives research support from Bayer. J.H.I. holds an investigator-initiated research grant from Baxter International Inc., serves as a member of a data safety monitoring board for Sanifit Therapeutics, is a member of the scientific advisory board for Alpha Young, and has served on advisory boards for AstraZeneca and Ardelyx. S.M.P has served as a consultant or on advisory boards for Astellas, AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Pfizer, Casma, Mission Therapeutics, Entrada, and Cytokinetics in the last 24 months. C.R.P. is a member of the advisory board of and owns equity in RenalytixAI. He also serves as a consultant for Genfit and Novartis.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
